These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1611835)

  • 1. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
    Krentz AJ; Honigsberger L; Ellis SH; Hardman M; Nattrass M
    Diabet Med; 1992 Jun; 9(5):463-8. PubMed ID: 1611835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P
    J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
    Florkowski CM; Rowe BR; Nightingale S; Harvey TC; Barnett AH
    Diabetes; 1991 Jan; 40(1):129-33. PubMed ID: 1901808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
    Ziegler D; Mayer P; Rathmann W; Gries FA
    Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
    Valensi P; Attali JR; Gagant S
    Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
    Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
    Boland OM; Blackwell CC; Clarke BF; Ewing DJ
    Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
    Faes TJ; Yff GA; DeWeerdt O; Lanting P; Heimans JJ; Bertelsmann FW
    J Neurol; 1993; 240(3):156-60. PubMed ID: 8482988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.
    Cameron NE; Cotter MA
    Br J Pharmacol; 1992 Dec; 107(4):939-44. PubMed ID: 1467842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats: effects of extracellular glucose concentration and of aldose reductase inhibition.
    Carrington AL; Ettlinger CB; Tomlinson DR
    J Diabetes Complications; 1994; 8(1):33-9. PubMed ID: 8167385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
    Sundkvist G; Lilja B; Rosén I; Agardh CD
    Acta Med Scand; 1987; 221(5):445-53. PubMed ID: 3111179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group.
    Laudadio C; Sima AA
    J Diabetes Complications; 1998; 12(3):121-7. PubMed ID: 9618066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
    Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
    Fagius J; Brattberg A; Jameson S; Berne C
    Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB; Herold K; Bartkus C
    Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB; Towle VL; Maselli R; Herold K
    Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.